<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37120076</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-2990</ISSN><JournalIssue CitedMedium="Internet"><Volume>366</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of the medical sciences</Title><ISOAbbreviation>Am J Med Sci</ISOAbbreviation></Journal><ArticleTitle>Post-COVID health-related quality of life and somatic symptoms: A national survey in Japan.</ArticleTitle><Pagination><StartPage>114</StartPage><EndPage>123</EndPage><MedlinePgn>114-123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjms.2023.04.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9629(23)01165-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">The characteristics and risk factors of post-COVID-19 condition affecting health-related quality of life and the symptom burden are unclear.</AbstractText><AbstractText Label="METHODS">The present, cross-sectional study used the JASTIS (Japan Society and New Tobacco Internet Survey) database. EQ-5D-5L and Somatic Symptom Scale-8 were used to assess health-related quality of life and somatic symptoms, respectively. The participants were classified into a no-COVID-19, COVID-19 not requiring oxygen therapy or COVID-19 requiring oxygen therapy group. First, the entire cohort was analyzed. Then, sensitivity analysis was performed after excluding patients in the no-COVID-19 group with a history of close contact with individuals known to have the disease.</AbstractText><AbstractText Label="FINDINGS">In total, 30130 individuals (mean age: 47.8; females: 51.2%), including 539 and 805 with COVID-19 requiring and not requiring oxygen therapy, respectively, participated. The analysis of the entire cohort as well as the sensitivity analysis demonstrated that individuals with a history of COVID-19 had significantly lower EQ-5D-5L and significantly higher SSS-8 scores than those with no COVID-19 history. The group requiring oxygen therapy was associated with significantly lower EQ-5D-5L and higher SSS-8 scores than the group not requiring oxygen therapy. Propensity-score matching confirmed these results. Furthermore, two or more COVID-19 vaccinations were independently associated with high EQ-5D-5L and low SSS-8 scores (P&#xa0;&lt;&#xa0;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">The participants with a COVID-19 history, especially those with severe disease, had a significantly higher somatic symptom burden. Analysis after adjusting for potential confounders found that their quality-of-life was also severely affected. Vaccination is crucial to addressing these symptoms, especially in high-risk patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kamata</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, Aizu Medical Center, Fukushima Medical University, Aizu, Fukushima, Japan; Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Fujita Health University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokuda</LastName><ForeName>Yasuharu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Muribushi Okinawa Center for Teaching Hospitals, Okinawa, Japan; Tokyo Foundation for Policy Research, Tokyo, Japan. Electronic address: yasuharu.tokuda@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takamatsu</LastName><ForeName>Akane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taniguchi</LastName><ForeName>Kiyosu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Tokyo Foundation for Policy Research, Tokyo, Japan; National Hospital Organization, Mie Medical Center, Mie, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibuya</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Tokyo Foundation for Policy Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabuchi</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Tokyo Foundation for Policy Research, Tokyo, Japan; Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Sci</MedlineTA><NlmUniqueID>0370506</NlmUniqueID><ISSNLinking>0002-9629</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071896" MajorTopicYN="Y">Medically Unexplained Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Health-related quality of life</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Somatic symptoms</Keyword></KeywordList><CoiStatement>Declaration Competing of Interest The authors declare no conflicts of interest in this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>29</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37120076</ArticleId><ArticleId IdType="pmc">PMC10140465</ArticleId><ArticleId IdType="doi">10.1016/j.amjms.2023.04.018</ArticleId><ArticleId IdType="pii">S0002-9629(23)01165-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen T., Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis I., Fonseca-Rodriguez O., Farrington P., et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8984137</ArticleId><ArticleId IdType="pubmed">35387772</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes E.K., Zambrano L.D., Anderson K.N., et al. Coronavirus disease 2019 case surveillance - United States, january 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(24):759&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302472</ArticleId><ArticleId IdType="pubmed">32555134</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>World health organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for disease control and prevention. Long COVID or Post-COVID Conditions. 2022; https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>Ledoford H. How common is long COVID? Why studies give different answers. Nature. 2022;606:852&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pubmed">35725828</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Khunti K., Nafilyan V., et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta J., Wiernik E., Robineau O., et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among french adults during the COVID-19 pandemic. JAMA Intern Med. 2022;182(1):19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8576624</ArticleId><ArticleId IdType="pubmed">34747982</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P., Patel K., Pinto C., et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J Med Virol. 2022;94(1):253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>The Japan &#x201c;society and new tobacco&#x201d; internet survey 2022 https://jastis-study.jp.</Citation></Reference><Reference><Citation>Rakuten Insight. 2022 https://insight.rakuten.co.jp/en/aboutus.html.</Citation></Reference><Reference><Citation>Japan broadcasting coporation (Nihon Hoso Kyokai: NHK). Special Site for COVID-19, 2022. https://www3.nhk.or.jp/news/special/coronavirus/.</Citation></Reference><Reference><Citation>Fernandez-de-Las-Penas C., Rodriguez-Jimenez J., Moro-Lopez-Menchero P., et al. Psychometric properties of the Spanish version of the EuroQol-5D-5L in previously hospitalized COVID-19 survivors with long COVID. Sci Rep. 2022;12(1):12605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307967</ArticleId><ArticleId IdType="pubmed">35871259</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiroiwa T., Noto S., Fukuda T. Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24(8):1193&#x2013;1202.</Citation><ArticleIdList><ArticleId IdType="pubmed">34372985</ArticleId></ArticleIdList></Reference><Reference><Citation>Gierk B., Kohlmann S., Kroenke K., et al. The somatic symptom scale-8 (SSS-8): a brief measure of somatic symptom burden. JAMA Intern Med. 2014;174(3):399&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">24276929</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuzuki S., Miyazato Y., Terada M., Morioka S., Ohmagari N., Beutels P. Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients. Health Qual Life Outcomes. 2022;20(1):125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388960</ArticleId><ArticleId IdType="pubmed">35986269</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L.B.S., Saydah S., Boehmer T.K., Adjei S., Gray S., Harris A.M. Post&#x2013;COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years &#x2014; United States, march 2020&#x2013;november 2021. MMWR Morb Mortal Wkly Rep. 2022;71(21):713&#x2013;717.</Citation></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895. e820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.E., Huh K., Park Y.J., Peck K.R., Jung J. Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection. JAMA. 2022;328(9):887&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449799</ArticleId><ArticleId IdType="pubmed">35867050</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E., Levi R., Sarti R., et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022;328(7):676&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart S., Newson L., Briggs T.A., Grammatopoulos D., Young L., Gill P. Long COVID risk - a signal to address sex hormones and women's health. Lancet Reg Health Eur. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8561426</ArticleId><ArticleId IdType="pubmed">34746909</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13(1):3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>